Articles from Aptar Digital Health

Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, today announced that the U.S Food and Drug Administration (FDA) has granted 510(k) clearance for HeroTracker® Sense as a Class II medical device. This milestone recognizes HeroTracker® Sense - a Bluetooth-enabled sensor - as an innovative connected add-on for pressurized Metered Dose Inhalers (pMDIs), transforming traditional inhalers into smart, data-driven devices for patients and healthcare professionals.

Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, today announces the positive results from the SPEED1 survey, showcasing the impact of the iPUMP® connected assistant on adherence to Stallergenes Greer’s sublingual liquid immunotherapy (SLIT). The results will be presented by Stallergenes Greer, a global leader in allergy therapeutics and long-standing partner of Aptar Digital Health, at the upcoming CFA congress (Congrès Francophone d'Allergologie) in Paris, France from April 15 to 18, 2025.

Aptar Digital Health, a global leader in digital health solutions, connected devices, data and study services, today announced a collaboration with the Quality of Life (QoL) technologies lab, University of Geneva, Switzerland, to advance migraine scientific research. This innovative study aims to deepen the overall understanding of migraine and help improve the lives of those affected by the condition. Its primary objective is to investigate the potential relationship between daily life digital biomarkers and migraine, focusing on how lifestyle factors may influence migraine occurrences and severity. The migraine-related data will be collected through Aptar Digital Health’s mobile application Migraine Buddy®, one of the largest online communities empowering individuals that suffer from migraines.

Aptar Digital Health, a global leader in digital health solutions including Software as a Medical Device (SaMD), digital Patient Support Programs, connected devices, and disease management platforms, today announced a collaboration with Guy’s and St Thomas’ NHS Foundation Trust, a leading Trust in London, United Kingdom, to evaluate the impact of Aptar Digital Health’s Respiratory Disease Management Platform, ADH Respiratory DMP, on asthma patients. Both organizations are partnering with the Clinical Research Organization (CRO) Lindus Health to execute the study.

Aptar Digital Health, a global leader in digital health solutions (Software as a Medical Device (SaMD) and digital Patient Support Programs), connected devices and disease management, today announced a collaboration with SHL Medical, a world-leading solutions provider of advanced drug delivery systems such as autoinjectors, pen injectors and innovative specialty delivery systems. The collaboration will extend SHL Medical’s connected device technologies by integrating Aptar Digital Health’s SaMD platform to provide comprehensive solutions to help patients on injectable therapies manage their disease.

Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs) and disease management solutions, and Iona Mind, a global leader in low-intensity Cognitive Behavioral Therapy (CBT) solutions for mental health, today announced a partnership to help support patients with chronic diseases to manage their psychological stress and emotional wellbeing. Benefiting from the combined capabilities and digital platforms of both organizations, the partnership will provide integrated solutions to pharmaceutical partners aiming to enhance patient experiences.